SCHEDULE: Vanguard Discloses 5.06% Stake in Oruka Therapeutics

The Vanguard Group has reported a 5.06% beneficial ownership stake in Oruka Therapeutics Inc. as of December 31, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 2,453,530 shares of Oruka Therapeutics Inc. Common Stock.
• This ownership represents 5.06% of the total class of securities.
• Vanguard holds shared voting power over 291,185 shares and shared dispositive power over all 2,453,530 beneficially owned shares.
• An internal realignment at The Vanguard Group, Inc. on January 12, 2026, resulted in it no longer performing portfolio management or administering proxy voting services.
• Following the realignment, certain Vanguard subsidiaries or business divisions are expected to report beneficial ownership separately (on a disaggregated basis).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as it confirms a significant institutional investor's stake in Oruka Therapeutics, implying a degree of confidence, albeit passive, in the company's long-term prospects.

Positives

• A major institutional investor like The Vanguard Group holding a significant stake (over 5%) can be seen as a vote of confidence in Oruka Therapeutics Inc.'s long-term prospects.

Future Outlook

The filing does not provide forward-looking statements or guidance regarding Oruka Therapeutics Inc.'s future performance or The Vanguard Group's future investment intentions beyond the disclosure of its current stake and the internal realignment.

Management Comments

• The Vanguard Group certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing indicates a passive investment by a large institutional investor like The Vanguard Group. Such filings are routine disclosures when an entity crosses the 5% beneficial ownership threshold. For Oruka Therapeutics, this signifies that a major asset manager has allocated capital to its stock, which can be viewed positively by the market, suggesting institutional validation.

Comparison to Industry Standards

• StockSavvy.ai observes that institutional ownership by major asset managers like The Vanguard Group is a common feature across publicly traded companies, particularly those with established market presence or promising growth trajectories.
• While this filing does not provide specific performance metrics for Oruka Therapeutics to compare against industry peers, the mere presence of a significant Vanguard stake aligns with typical institutional investment patterns in the biotechnology or pharmaceutical sector, where long-term growth potential often attracts such passive investments.
• For example, similar stakes are often seen in companies like Moderna (MRNA) or BioNTech (BNTX) by large index funds or passive managers, indicating a broad market belief in the sector's prospects.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major institutional investor like Vanguard may enhance investor confidence and potentially contribute to stock stability.
• Company Management: Awareness of a large passive institutional holder may influence management's focus on long-term value creation, aligning with Vanguard's investment philosophy.

Next Steps

• Following an internal realignment on January 12, 2026, certain subsidiaries or business divisions of The Vanguard Group, Inc. anticipate reporting beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on SEC Release No. 34-39538.

Key Dates

Recommendation

The filing indicates a significant, passive institutional stake by The Vanguard Group, which is generally a positive sign of long-term confidence. However, a Schedule 13G filing does not provide operational or financial performance details of Oruka Therapeutics Inc. to warrant a 'buy' or 'sell' recommendation. It primarily confirms a large investor's position. Therefore, a 'hold' recommendation is appropriate for existing investors, while new investors would need to conduct further due diligence on Oruka Therapeutics' fundamentals before making an investment decision.

Keywords

Oruka Therapeutics, Vanguard Group, Schedule 13G, beneficial ownership, institutional investment, common stock, equity stake, investment adviser